Pharmaceutical News

RSS

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Existing drug mitigates muscle loss from GLP-1 medications

Millions of Americans are currently taking GLP-1 medications such as Ozempic or Wegovy for weight loss.

2 Jun 2026

Study finds serious blood-related side effects associated with antibody-drug conjugates

A major real-world study by University of California, Irvine pharmacy researchers has found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies.

2 Jun 2026

GLP-1 medications linked to lower breast cancer risk in women

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penn's Abramson Cancer Center.

2 Jun 2026

Southwest Research Institute evaluates NASA's medication handling practices

Southwest Research Institute evaluated NASA's medication handling practices, which currently call for removing medications from their original packaging and storing them in resealable plastic bags.

2 Jun 2026

Most psoriasis patients can safely reduce their dosage of biologics

Three-quarters of people who respond well to the newest types of biologics for psoriasis can safely reduce their dosage, often even by half.

1 Jun 2026

PromptSE AI predicts drug side effects by reasoning through biological clues

PromptSE uses structured LLM prompting to generate pharmacologically relevant side-effect representations, then feeds them into deep learning models to predict drug-side effect associations. In benchmark testing, PromptSE improved prediction performance, while PromptSE+ further boosted results by adding multi-modal drug information and graph-based refinement for sparse data.

1 Jun 2026

Global policy gaps slow biosimilar adoption and access

Nine out of 10 prescriptions are filled by generic drugs - FDA-approved carbon copies of brand-name drugs with expired patents.

1 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

Common anemia drugs may help slow cancer growth and progression

Common medications used to treat anemia may also slow down cancer cell growth, according to new research from Finland.

28 May 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Vaginal bromocriptine may ease pain and heavy bleeding in adenomyosis

A pilot randomized controlled trial found that vaginal bromocriptine reduced menstrual bleeding, pelvic pain, menstrual duration, and cycle irregularity in women with adenomyosis compared with routine treatment.

27 May 2026

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced dose-dependent reductions in circulating PCSK9 protein and LDL cholesterol in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

26 May 2026

Retatrutide reshapes metabolism in obesity and type 2 diabetes, study finds

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with obesity, with or without type 2 diabetes. These biomarker changes suggest improved metabolic health, but the post-hoc analysis remains hypothesis-generating and does not prove direct clinical benefit.

26 May 2026

Could blocking inflammation help treat difficult-to-treat depression?

A small proof-of-concept RCT found that tocilizumab, an IL-6 receptor blocker, showed a non-significant but clinically suggestive pattern of improvement in difficult-to-treat depression linked to low-grade inflammation. The study found that baseline hs-CRP, rather than IL-6, may help identify patients most likely to respond, supporting larger trials of immune-targeted depression care.

22 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026

GLP-1 drugs may help curb addiction by targeting reward pathways

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways. Most evidence remains preclinical, with limited early human data, so larger clinical trials are needed before these drugs can be recommended for addiction treatment.

21 May 2026